1. |
Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma[J]. Lancet, 2003, 362(9399):1907-1917.
|
2. |
Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis:from genes to environment[J]. Nature Rev Cancer, 2006, 6(9):674-687.
|
3. |
El-Serag HB, Rudolph KL. Hepatocellular carcinoma:epidemiology and molecular carcinogenesis[J]. Gastroenterology, 2007, 132(7):2557-2576.
|
4. |
Poon D, Anderson BO, Chen LT, et al. Management of hepatocellular carcinoma in Asia:consensus statement from the Asian Oncology Summit[J]. Lancet Oncol, 2009, 10(11):1111-1118.
|
5. |
Bruix J, Sherman M. Practice Guide lines Committee, American Association for the Study of Liver Diseases. Management of hepa tocellular carcinoma[J]. Hepatology, 2005, 42(5):1208-36.
|
6. |
Poon TP, Fan ST, Wong J. Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma[J]. Ann Surg, 2000, 232(1):10-24.
|
7. |
Portolani N, Coniglio A, Ghidoni S, et al. Early and late recurrence after liver resection for hepatocellular carcinoma:prognostic and therapeutic implications[J]. Ann Surg, 2006, 243(2):229-235.
|
8. |
Wang SM, Ooi LL, Hui KM. Upregulation of Rac GTPase-activating protein 1 is significantly associated with the early recurrence of human hepatocellular carcinoma[J]. Clin Cancer Res, 2011, 17(18):6040-6051.
|
9. |
Futreal PA, Coin L, Marshall M, et al. A census of human cancer genes[J]. Nature reviews, 2004, 4(3):177-183.
|
10. |
Maere S, Heymans K, Kuiper M. BiNGO:a Cytoscape plugin to assess overrepresentation of gene ontology categories in biological networks[J]. Bioinformatics, 2005, 21(16):3448-3449.
|
11. |
Xie C, Mao X, Huang J, et al. KOBAS 2.0:a web server for annotation and identification of enriched pathways and diseases[J]. Nucleic Acids Res, 2011, 39(Web Server issue):W316-W322.
|
12. |
Lamb J, Crawford ED, Peck D, et al. The Connectivity Map:using gene-expression signatures to connect small molecules, genes, and disease[J]. Science, 2006, 313(5795):1929-1935.
|
13. |
Zaman SN, Johnson RD, Johnson PJ, et al. Risk factors in development of hepatocellular carcinoma in cirrhosis:prospective study of 613 patients[J]. Lancet, 1985, 1(8442):1357-1360.
|
14. |
Tsukuma H, Hiyama T, Tanaka S, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease[J]. N Engl J Med, 1993, 328(25):1797-1801.
|
15. |
Bolondi L, Sofia S, Siringo S, et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma:a cost effectiveness analysis[J]. Gut, 2001, 48(2):251-259.
|
16. |
Yeh FS, Yu MC, MoC C, et al. Hepatitis B virus, aflatoxins, and hepatocellular carcinoma in southern Guangxi China[J]. Cancer Res, 1989, 49(9):2506-2509.
|
17. |
Thomas MB, ZhuAX. Hepatocellular carcinoma:the need for progress[J]. J Clin Oncol, 2005, 23(13):2892-2899.
|
18. |
Lin YM, Chang JH, Yeh KT, et al. Disturbance of circadian gene expression in hepatocellular Carcinoma[J]. Mol Carcinog, 2008, 47(12):925-933.
|
19. |
Jiang R, Tan Z, Deng L, et al. Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3[J]. Hepato-logy, 2011, 54(3):900-909.
|
20. |
Zhou Q, Lui VW, Yeo W. Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma[J]. Future Oncol, 2011, 7(10):1149-1167.
|
21. |
Hanahan D, Weinberg RA. Hallmarks of cancer:the next generation[J]. Cell, 144(5):646-674.
|
22. |
Martirosyan A, Clendening JW, Goard CA, et al. Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin:potential therapeutic relevance[J]. BMC Cancer, 2010, 10:103.
|
23. |
Sanli T, Liu C, Rashid A, et al. Lovastatin sensitizes lung cancer cells to ionizing radiation:modulation of molecular pathways of radioresistance and tumor suppression[J]. J Thorac Oncol, 2011, 6(3):439-450.
|
24. |
Xu W, Lacerda L, Debeb BG, et al. The antihelmintic drug pyrvinium pamoate targets aggressive breast cancer[J]. PLoS One, 2013, 8(8):e71508.
|
25. |
Deng L, Lei Y, Liu R, et al. Pyrvinium targets autophagy addic tion to promote cancer cell death[J]. Cell Death Dis, 2013, 4:e614.
|
26. |
Fainstein V, Bodey GP, Bolivar R, et al. Moxalactam plus ticarcillin or tobramycin for treatment of febrile episodes in neutropenic cancer patients[J]. Arch Intern Med, 1984, 144(9):1766-1770.
|